HOME >> BIOLOGY >> NEWS
New Medication Means New Choices For Families Dealing With Alzheimers Disease

Hershey, Pa. -- A new study from Penn State's College of Medicine finds that when medication for Alzheimer's disease is offered to all patients, family members of patients in the early stages of Alzheimer's are the most likely to accept available treatment.

"When dealing with this terrible disease, families are faced with many extremely difficult decisions. One of those decisions is whether or not to treat their ill family member with this relatively new drug, that doesn't stop the disease, but slows the progression of the disease," says Paul Kettl, M.D., associate professor of psychiatry and acting chair of psychiatry at Penn State. Kettl is also chief of psychiatry with the Penn State Geisinger Health System in Hershey, Pa.

The results of the one-year study titled, "Family Treatment Decisions in Alzheimer's Disease," was presented today (June 3) at the American Psychiatric Association meeting in Toronto.

Kettl studied 60 patients with Alzheimer's disease who were admitted consecutively to the inpatient psychiatry unit at Hershey Medical Center. The one-year study asked families whether or not they wanted the patient to be treated with the drug donepezil or vitamin E. Both treatments do not stop the disease but significantly slow the progress of the disease. Donepezil has been widely prescribed by physicians for about a year.

"There were 28 people in the treatment group and 32 people in the non-treatment group. We found there was no difference based on age or sex," says Kettl. "The difference in treatment decisions was determined more by how far the disease had progressed. For patients who were in the early stages of the disease and often were cared for at home, families overwhelmingly chose to treat the patient. For those patients who lived in a nursing home and the disease was fairly advanced, families chose to withhold the treatment."

Kettl says these kinds of difficult ethical questions will have to
'"/>

Contact: Leilyn Perri
lperri@psghs.edu
717-531-8604
Penn State
3-Jun-1998


Page: 1 2

Related biology news :

1. Medication reconciliation, pharmacist involvement vital to reducing medication errors, study finds
2. Possible Dangers Of Taking Over-The-Counter Medications For Hepatitis C Patients
3. Common Anti-Viral Medication Prevents Severe Eye Herpes
4. Study Reviews Medication Use In Elderly Cardiac Patients After Discharge
5. Material Choices For The Chemical Industry
6. Families with severe form of bipolar disorder help scientists narrow the search for disease genes
7. Families with two or more children with autism sought for $10.2 million study
8. Sudden Cardiac Death May Run In Families
9. Vastly Different Virus Families May Be Related
10. Dealing with reams of data
11. New theory of cell death proposed in UCSB Alzheimers research

Post Your Comments:
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014The development of stem ... on the ability to characterize stem cell populations based ... Cross have discovered a new marker that is highly ... human umbilical cord blood, which they describe in an ... journal from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
(Date:4/17/2014)... German . ... also provide us with a continuous stream of information about ... sit still in a car the world glides by ... Seemingly without effort, our brain calculates self-motion from this "optic ... a steady gaze during our own movements. Together with biologists ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
Cached News: